Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DICLOFENAC vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Ankylosing spondylitis,Osteoarthritis,Rheumatoid arthritis,Acute migraine (oral formulation),Mild to moderate acute pain (off-label),Dysmenorrhea (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via CYP2C9 (major) and CYP3A4 (minor); undergoes glucuronidation. Metabolites include 4'-hydroxydiclofenac, 5-hydroxydiclofenac, and 3'-hydroxydiclofenac.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
>99% bound primarily to serum albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.1-0.2 L/kg (low distribution, reflects high protein binding). Clinical meaning: Limited extravascular distribution; primarily remains in vascular space.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral immediate-release: ~50% due to extensive first-pass metabolism; Topical: <10% systemic; Ophthalmic: minimal; IV: 100%.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR >30 m L/min: no adjustment. GFR 15-30 m L/min: use with caution, reduce dose, avoid if possible. GFR <15 m L/min: contraindicated.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Children ≥1 year: oral 0.5-1 mg/kg/dose twice daily; maximum 3 mg/kg/day or 150 mg/day. Children ≥14 years: same as adult.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lowest effective dose, e.g., 25-50 mg/day oral; increase cautiously. Avoid NSAIDs in advanced age due to GI and renal risks.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Diclofenac is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Cardiovascular risk: increased risk of thrombotic events, hypertension, and heart failure.,Gastrointestinal risk: increased risk of serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: monitor renal function in patients with preexisting renal disease, dehydration, or concomitant nephrotoxic agents.,Hepatic toxicity: elevated liver enzymes; rare cases of severe hepatic reactions.,Anaphylactoid reactions: can occur in patients with or without known NSAID hypersensitivity.,Fluid retention and edema: use with caution in patients with hypertension or heart failure.,Skin reactions: serious cutaneous adverse reactions such as Stevens-Johnson syndrome and DRESS.,Hematologic: prolonged bleeding time; use with caution in patients with coagulation disorders.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to diclofenac or any component of the formulation,History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in the setting of CABG surgery,Active GI bleeding,Severe uncontrolled heart failure,Advanced renal disease (unless dialysis is ongoing),Third trimester of pregnancy
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol as it increases risk of GI bleeding. Take with food or milk to minimize GI irritation. No specific food restrictions, but high-fat meals may delay absorption.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: Risk of oligohydramnios and fetal renal impairment with prolonged use. Third trimester: Avoid after 30 weeks gestation; risk of premature closure of ductus arteriosus, persistent pulmonary hypertension of the newborn, and oligohydramnios.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted in breast milk in low amounts; M/P ratio not reported. Use with caution; avoid in breastfeeding mothers with infants with thrombocytopenia or platelet dysfunction. Consider risk of infant renal impairment.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No dose adjustment recommended for pharmacokinetic changes; however, use at lowest effective dose for shortest duration. Avoid in third trimester due to fetal risks. Consider alternative analgesics in all trimesters.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Diclofenac is a potent NSAID with a short half-life, making it suitable for acute pain but requiring frequent dosing. It carries a higher risk of cardiovascular events compared to other NSAIDs; caution in patients with hypertension or heart disease. Enteric-coated formulations may delay onset but reduce GI irritation. Intravenous formulation allows for rapid analgesia but requires monitoring for hypertension and fluid retention. Diclofenac can cause elevation of liver enzymes; monitor LFTs with long-term use. It is available in combination with misoprostol to reduce GI ulcer risk.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting doctor.,Report signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds) or chest pain immediately.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Limit sun exposure and use sunscreen as this drug may increase sun sensitivity.,Do not use in third trimester of pregnancy as it may harm the unborn baby.,Store at room temperature away from moisture and heat.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Ximelagatran, an oral direct thrombin inhibitor, increases the risk of bleeding when coadministered with diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). The combination potentiates anticoagulant activity through additive inhibition of platelet aggregation and thrombin-mediated coagulation, elevating the risk of gastrointestinal hemorrhage and other serious bleeding events. Patients, particularly those with renal impairment or advanced age, require close monitoring for signs of bleeding."
"Acebutolol, a cardioselective beta-blocker, may attenuate the antihypertensive effect of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). Diclofenac inhibits cyclooxygenase, reducing prostaglandin synthesis, which can lead to sodium retention and increased vascular resistance, thereby counteracting the blood pressure-lowering effects of acebutolol. This interaction may result in diminished blood pressure control, potentially requiring dose adjustments of antihypertensive therapy."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DICLOFENAC vs ABSTRAL, answered by our medical review team.
DICLOFENAC is a NSAID that works by Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DICLOFENAC and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DICLOFENAC is: Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DICLOFENAC and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DICLOFENAC is classified as Category D/X. First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: R. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.